Start Submission

Reading: Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars


A- A+
dyslexia friendly


Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars


Juan V. Esplugues ,

Department of Pharmacology, University of Valencia/CIBERehd, Blasco Ibañez, 15, 46010 Spain, ES
X close

Bruno Flamion,

Department of Physiology and Pharmacology, University of Namur, 61 rue de Bruxelles, 5000 Namur Belgium, BE
X close

Lluis Puig

Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Sant Quintí, 89, 08041 Barcelona, Spain, ES
X close


The number of biosimilar medicines on the market is steadily increasing, due, in part, to patent expiration of several top-selling biologic medicines. These three e-learning modules discuss the basic concepts behind biosimilar medicines and highlight key regulatory considerations when using biosimilar medicines in medical practice.
How to Cite: V. Esplugues, J., Flamion, B. & Puig, L., (2016). Putting the “bio” in “biotherapeutics”/checkpoints for biosimilars/application of biosimilars. New Horizons in Translational Medicine. 3(3-4), p.161. DOI:
Published on 13 Oct 2016.
Peer Reviewed


  • PDF (EN)